Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Menconi

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Thyroid : Official Journal of the American Thyroid Association|June 20, 2015
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' OrbitopathyEleonora Sisti, Barbara Coco, Francesca Menconi, et al.
Thyroid : Official Journal of the American Thyroid Association|February 5, 2025
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves' Orbitopathy: A Retrospective Cohort StudyGiada Cosentino, Giulia Lanzolla, Simone Comi, et al.
Journal of Endocrinological Investigation|March 21, 2025
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimusSimone Comi, Giada Cosentino, Elena Sabini, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2003
Long-term safety of orbital radiotherapy for Graves' ophthalmopathyClaudio Marcocci, Luigi Bartalena, Roberto Rocchi, et al.
American Journal of Otolaryngology|April 19, 2022
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocolsIacopo Dallan, Lodovica Cristofani-Mencacci, Giacomo Fiacchini, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 13, 2016
VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPYMarenza Leo, Teresa Mautone, Ilaria Ionni, et al.
Journal of Endocrinological Investigation|March 25, 2026
Serum mTOR: an associative marker of Graves' orbitopathyGiulia Lanzolla, Giovanna Rotondo Dottore, Simone Comi, et al.
Thyroid : Official Journal of the American Thyroid Association|January 17, 2018
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional StudyElena Sabini, Barbara Mazzi, Maria Antonietta Profilo, et al.
European Journal of Endocrinology|February 10, 2015
Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological studyEleonora Sisti, Barbara Coco, Francesca Menconi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 2003
Preferential megalin-mediated transcytosis of low-hormonogenic thyroglobulin: a control mechanism for thyroid hormone releaseSimonetta Lisi, Aldo Pinchera, Robert T McCluskey, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Thyroid : Official Journal of the American Thyroid Association|June 20, 2015
Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' OrbitopathyEleonora Sisti, Barbara Coco, Francesca Menconi, et al.
Thyroid : Official Journal of the American Thyroid Association|February 5, 2025
Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves' Orbitopathy: A Retrospective Cohort StudyGiada Cosentino, Giulia Lanzolla, Simone Comi, et al.
Journal of Endocrinological Investigation|March 21, 2025
Serum levels of rapamycin predict the response of Graves' orbitopathy to sirolimusSimone Comi, Giada Cosentino, Elena Sabini, et al.
The Journal of Clinical Endocrinology and Metabolism|August 14, 2003
Long-term safety of orbital radiotherapy for Graves' ophthalmopathyClaudio Marcocci, Luigi Bartalena, Roberto Rocchi, et al.
American Journal of Otolaryngology|April 19, 2022
Functional outcomes and complications in refractory dysthyroid optic neuropathy management: Experience with 3 different surgical protocolsIacopo Dallan, Lodovica Cristofani-Mencacci, Giacomo Fiacchini, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 13, 2016
VARIABLES AFFECTING THE LONG-TERM OUTCOME OF GRAVES ORBITOPATHY FOLLOWING HIGH-DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPYMarenza Leo, Teresa Mautone, Ilaria Ionni, et al.
Journal of Endocrinological Investigation|March 25, 2026
Serum mTOR: an associative marker of Graves' orbitopathyGiulia Lanzolla, Giovanna Rotondo Dottore, Simone Comi, et al.
Thyroid : Official Journal of the American Thyroid Association|January 17, 2018
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional StudyElena Sabini, Barbara Mazzi, Maria Antonietta Profilo, et al.
European Journal of Endocrinology|February 10, 2015
Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological studyEleonora Sisti, Barbara Coco, Francesca Menconi, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 6, 2003
Preferential megalin-mediated transcytosis of low-hormonogenic thyroglobulin: a control mechanism for thyroid hormone releaseSimonetta Lisi, Aldo Pinchera, Robert T McCluskey, et al.
Pageof 6